
Psychedelics and cannabis-focused pharmaceutical company PharmaDrug Inc. (CSE:PHRX) (OTCQB:LMLLF) has completed a head-to-head potency comparator study of its two undisclosed DMT-analogue candidates for the treatment of primary open angle glaucoma.

Psychedelics and cannabis-focused pharmaceutical company PharmaDrug Inc. (CSE:PHRX) (OTCQB:LMLLF) has completed a head-to-head potency comparator study of its two undisclosed DMT-analogue candidates for the treatment of primary open angle glaucoma.